PMID- 15746650
OWN - NLM
STAT- MEDLINE
DCOM- 20050329
LR  - 20220228
IS  - 0022-2143 (Print)
IS  - 0022-2143 (Linking)
VI  - 145
IP  - 2
DP  - 2005 Feb
TI  - Association between reduced low density lipoprotein oxidation and inhibition of 
      monocyte chemoattractant protein-1 production in statin-treated subjects.
PG  - 83-7
AB  - Monocyte chemoattractant protein-1 (MCP-1) is essential in atherogenesis. 
      Oxidized lipids regulate MCP-1 expression and release from mononuclear cells. In 
      this study we investigated (1) whether statin therapy reduces lipopolysaccharide 
      (LPS)-stimulated MCP-1 production in human whole-blood samples and (2) the 
      relationships between in vitro low-density lipoprotein (LDL) oxidation and MCP-1 
      production. Fasting blood samples were obtained from 55 healthy nonsmoking adults 
      with moderate hypercholesterolemia who were participating in a randomized 
      double-blind 8-week trial comparing the effects of statin therapy with those of 
      placebo on cytokine production. Samples were analyzed for resistance to 
      copper-mediated LDL oxidation (lag time in minutes), as well as MCP-1- and 
      interleukin-8 (IL-8)-stimulated production. Statin therapy reduced MCP-1 
      production (mean +/- SD) -161 +/- 399 pg/mL/mm 3 white cells) compared with 267 
      +/- 985 pg/mL/mm 3 in the placebo group, but changes were not different between 
      active and placebo groups ( P = .13). Statin therapy also increased lag times 
      (median [interquartile range]; 20.5 [7.0-51.2] minutes vs -17.0 [-5.3-16.5] 
      minutes; P = .067 for group difference). Inhibition of MCP-1 production 
      correlated with prolongation of lag time ( r = .46, P = .0056) in statin-treated 
      subjects. Statin therapy reduced MCP-1 production in the whole blood of human 
      subjects and these changes were correlated with improvement in LDL oxidative 
      resistance.
FAU - Rosenson, Robert S
AU  - Rosenson RS
AD  - Preventive Cardiology Center, Division of Cardiology, Department of Medicine, 
      Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA. 
      r-rosenson@northwestern.edu
FAU - Tangney, Christine C
AU  - Tangney CC
FAU - Levine, Daniel M
AU  - Levine DM
FAU - Parker, Thomas S
AU  - Parker TS
FAU - Gordon, Bruce R
AU  - Gordon BR
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - J Lab Clin Med
JT  - The Journal of laboratory and clinical medicine
JID - 0375375
RN  - 0 (Chemokine CCL2)
RN  - 0 (Cholesterol, LDL)
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - 0 (Lipoproteins, LDL)
RN  - 0 (oxidized low density lipoprotein)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Chemokine CCL2/*blood
MH  - Cholesterol, LDL/*blood
MH  - Female
MH  - Humans
MH  - Hydroxymethylglutaryl-CoA Reductase Inhibitors/*administration & dosage
MH  - Hypercholesterolemia/blood/*drug therapy
MH  - Leukocytes, Mononuclear/metabolism
MH  - Lipoproteins, LDL/*blood
MH  - Male
MH  - Middle Aged
MH  - Oxidation-Reduction
EDAT- 2005/03/05 09:00
MHDA- 2005/03/30 09:00
CRDT- 2005/03/05 09:00
PHST- 2005/03/05 09:00 [pubmed]
PHST- 2005/03/30 09:00 [medline]
PHST- 2005/03/05 09:00 [entrez]
AID - S0022214304003087 [pii]
AID - 10.1016/j.lab.2004.11.012 [doi]
PST - ppublish
SO  - J Lab Clin Med. 2005 Feb;145(2):83-7. doi: 10.1016/j.lab.2004.11.012.